MedTrace Logo

MOST: Mediterranean Oncology Senior Tests

NCT02148731 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 180

Last updated 2019-01-15

No results posted yet for this study

Summary

MOST is a longitudinal study whose aim is to test the hypothesis that frailty markers are better at detecting vulnerable patients and that they are a better "Adverse Events" predictive tool than the CGA (Comprehensive Geriatric Assessment) in older cancer patients referred for chemotherapy. The second hypothesis is that a brief screening tool based on a combination of some frailty markers and some used in the CGA would help the oncologist detect patients requiring a more complete geriatric assessment

Conditions

  • Colon Cancer Patients Receiving Chemotherapy in the Adjuvant or Metastatic Setting
  • Aged 70 or Older

Interventions

OTHER

Frailty markers

Brief screening assessment, CGA and frailty markers will be evaluate at inclusion. CGA and frailty markers will be evaluated at 3, 6, 12 and 18 months after the beginning of chemotherapy. Criteria for toxicity and adverse outcomes will be recorded at each cycle or visits

Sponsors & Collaborators

  • Association Sud pour la Recherche en Oncogériatrie

    lead OTHER

Principal Investigators

  • Frédérique RETORNAZ, MD · Association Sud pour la Recherche en Oncogériatrie

Eligibility

Min Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2014-12-31
Completion
2015-12-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02148731 on ClinicalTrials.gov